An Immunohistochemical Study of bcl-2 and p53 Protein Expression in Pancreatic Carcinomas

REFERENCES

• Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993;53:4701–14.
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nunez G, Millian C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348: 334–6.
   Google Scholar
• Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991;65:1097–8.
   PubMed Web of Science ®Google Scholar
• Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879–86.
   PubMed Web of Science ®Google Scholar
• Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690–4.
   PubMed Web of Science ®Google Scholar
• Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The bcl-2 protein; a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499–504.
   PubMed Web of Science ®Google Scholar
• Hurlimann J, Larrinaga B, Vala DLM. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995;426: 163–8.
   Google Scholar
• Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237–41.
   PubMed Web of Science ®Google Scholar
• Saegusa M, Takano Y, Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 1995;121: 357–63.
   Google Scholar
• Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Clesry K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705–8.
   PubMed Web of Science ®Google Scholar
• Barton CM, Staddon SL, Hughes CM, Hall PA, O’Sullivan C, Kloppel G, et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991;64: 1076–82.
   Google Scholar
• Suwa H, Ohshio G, Okada N, Wang Z, Fukumoto M, Imamura T, et al. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 1997;40:649–53.
   Google Scholar
• Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359:552–4.
   PubMed Web of Science ®Google Scholar
• Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53- independent mechanisms inhibitable by Bcl-2. Cell 1994;79: 329–39.
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimichi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352: 345–7.
   Google Scholar
• Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54: 2095–7.
   Google Scholar
• Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, et al. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Can Res 1996;2:2015–22.
   PubMedGoogle Scholar
• Gibson JB. Histological typing of tumours of the liver, biliary tract and pancreas. International histological classifications of the tumours. Geneva: WHO; 1978.
   Google Scholar
• Klöppel G, Lingenthal G, Vonbulow M, Kern HF. Histological and fine structual features of pancreatic ductal adenocarcinomas in relation to growth and prognosis:studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases. Histopathology 1985;9: 841–56.
   Google Scholar
• Ohshio G, Yoshioka H, Manabe T, Sakahara H, Yamabe H, Imamura M, et al. Expression of sialosyl-Tn antigen (monoclonal antibody MLS102 reactive) in normal tissues and malignant tumors of the digestive tract. J Cancer Res Clin Oncol 1994;29:325–30.
   Google Scholar
• Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88:6961–5.
   PubMed Web of Science ®Google Scholar
• LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993;142: 743–53.
   Google Scholar
• Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasis. Cancer 1994;73: 2900–4.
   Google Scholar
• Doussis IA, Pezzella F, Lane DP, Gatter KC, Phil D, Mason DY. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin’s disease. Am J Clin Pathol 1993;99: 663–7.
   PubMed Web of Science ®Google Scholar